

REMARKS

Upon entry of the foregoing amendments, claims 1–4, 10–14, 16, 18, 19, 25 and 26 are pending. Applicants have amended claims 3 and 4 to correct antecedent basis. Thus, claims 3 and 4 now recite “polynucleotides.” Basis for these amendments can be found in the specification as originally filed, and in particular, in originally filed claims 1 and 2. Applicants have amended claim 13 to correct improper dependency. Thus, claim 13 now recites “the host cell of claim 12.” Applicants have amended claim 19 to correct clerical errors and improper dependency. Thus, claim 19 now recites “the vaccine vector of claim 16.” Applicants have amended claim 25 to correct clerical errors. Applicants have added new claims 38 and 39 to more accurately claim the present invention. New claims 38 and 39 further limit the type of host cells to be used in the present invention. Specifically, new claims 38 and 39 are directed to mammalian cells and human cells respectively. Basis for these amendments can be found in the specification as originally filed, and in particular, at pg. 14, lines 9–14; pg. 15, line 31; and in originally filed claim 17.

These amendments add no new matter.

Co-Pending Applications

Applicants acknowledge the Examiner’s request regarding copies of claims, correlated with the serial number of the case in which they appear, for each pending application directed to the pending subject matter.

Applicants respectfully submit that acquiescing to the Examiner’s request of providing copies of pending claims would be unduly onerous and expensive for Applicants. Applicants have **no obligation to provide the Examiner with copies of claims in any pending applications.** In fact, Applicants submit that, under M.P.E.P. §804, it is the Examiner’s burden to identify any potential statutory and/or “obvious-type” double patenting rejections. *See,* M.P.E.P. §804(I)(B), which states:

Occasionally, the examiner becomes aware of two copending applications filed by the same inventive entity, or by different inventive entities having a common

Applicants: Murdin *et al.*
Serial No. 09/428,122

inventor, and/or that are filed by a common assignee that would raise an issue of double patenting if one of the applications became a patent.

However, Applicants agree to provide the Examiner copies of the requested claims upon determination of allowable subject matter in the present application.

Drawings

Applicants acknowledge the Draftsperson's objection to the Drawings filed in the present application.

Applicants will provide formal drawings upon determination of allowable subject matter in the present application.

Oath/Declaration

Applicants acknowledge the Examiner's objection to the Declaration as filed in the present application. Applicants have enclosed herewith an executed Declaration. Accordingly, Applicants believe that the present objection is now moot.

Specification

The Examiner has objected to the Specification as having various informalities.

Applicants have amended the Specification to correct these informalities. Accordingly, Applicants believe that the present objection is now moot.

Provisional Double Patenting Rejection over Co-pending Applications

The Examiner has provisionally rejected claims 1–4, 10–14, 16–19, 25 and 26 under 35 U.S.C. §101 as claiming the same invention as that of claims 1, 20, 21, 25–28, 32–35, 41 and 42 of co-pending application U.S.S.N. 09/376,770 ("770").

Applicants traverse. 37 CFR §1.78(b) provides that when two or more applications filed by the same Applicant contain conflicting claims, elimination of such claims from all but one application may be required in the absence of good and sufficient reason for their retention

during pendency in more than one application. However, the M.P.E.P. clearly states that “[t]his paragraph is appropriate only when the conflicting claims are **patentably distinct**. See MPEP §822. *See also*, In re Zickendraht, 319 F.2d 225, 138 USPQ 22 (CCPA 1963) (where the Court held that the doctrine is well established in that claims in different applications need be more than merely different in form or content and that **patentable distinction must exist to entitle applicants to a second patent**).

The ‘770 application is a co-pending application having the both the same inventive entity and assignee. However, both applications are directed to distinct sequences encoding *different Chlamydia* polypeptides. Applicants have attached herewith an alignment comparison between the polypeptide of the present application with those disclosed by U.S.S.N. 09/376,770 (Exhibits A and B). The comparisons clearly show that the polypeptides according to the present invention are **completely different** from those disclosed in the ‘770 application.

Accordingly, in light of the arguments above, Applicants respectfully request reconsideration and withdrawal of the present provisional double patenting rejection.

35 U.S.C. §112, First Paragraph Rejections

The Examiner has rejected claims 1–4, 10–14, 16–19, 25 and 26 under 35 U.S.C. §112, first paragraph as containing subject matter which was not described in the Specification in such a way as to enable one skilled in the art to make and/or use the invention, stating that the Specification is not enabled for a polynucleotide encoding a polypeptide having a sequence that is “at least 75% homologous” to SEQ ID NO:2 and “functional fragments thereof.” Specifically, the Examiner has alleged that:

Without a clear and unambiguous description of how to perform the comparison, the scope of the claims can not be envisaged (*sic*). Without a specific disclosure of the parametric values used in the algorithm, the sequence identity between two sequences has no common meaning within the art and therefore, one of ordinary skill in the art cannot be sure of the sequences embraced by the claims and would not be able to make and use those polynucleotide or polypeptide sequence homologs as recited in the instant claims, without undue experimentation.

See e.g., December 13, 2000 Office action at pg. 5.

Applicants traverse. Methods and computational programs for conducting sequence comparisons for homology are well known within the art. Homology is typically measured using **sequence analysis software** (*e.g.*, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). Similar amino acid sequences are aligned to obtain the maximum degree of homology (*i.e.*, identity). To this end, it may be necessary to artificially introduce gaps into the sequence. Once the optimal alignment has been set up, the degree of homology (*i.e.*, identity) is established by recording all of the positions in which the amino acids of both sequences are identical, relative to the total number of positions.

The Specification also describes a preferred method for determining amino acid similarities, including amino acid sequence homology:

One particularly preferred method of determining amino acid similarities is the PAM25O matrix described in Dayhoff *et al.*, 5 ATLAS OF PROTEIN SEQUENCE AND STRUCTURE 345-352 (1978 & Supp.), incorporated by reference herein. A similarity score is first calculated as the sum of the aligned pairwise amino acid similarity scores. Insertions and deletions are ignored for the purposes of percent homology and identity. Accordingly, gap penalties are not used in this calculation. The raw score is then normalized by dividing it by the geometric mean of the scores of the candidate compound and the reference sequence. The geometric mean is the square root of the product of these scores. The normalized raw score is the percent homology.

See e.g., Specification at pg. 9, lines 15–23. Furthermore, the Specification specifically and clearly defines a "homologous amino acid sequence" as:

an amino acid sequence that differs from an amino acid sequence shown in SEQ ID NO: 2, only by one or more conservative amino acid substitutions, or by one or more non-conservative amino acid substitutions, deletions, or additions located at positions at which they do not destroy the specific antigenicity of the polypeptide. Preferably, such a sequence is at least 75%, more preferably 80%, and most preferably 90% identical to an amino acid sequence shown in SEQ ID NO: 2. Homologous amino acid sequences include sequences that are identical or substantially identical to an amino acid sequence as shown in SEQ ID NO: 2.

Id at pg. 8, lines 21–29. The Specification also describes amino acid sequence identity and conservative substitutions as:

By "amino acid sequence substantially identical" is meant a sequence that is at least 90%, preferably 95%, more preferably 97%, and most preferably 99% identical to an amino acid sequence of reference and that preferably differs from the sequence of reference, if at all, by a majority of conservative amino acid substitutions. Conservative amino acid substitutions typically include substitutions among amino acids of the same class. These classes include, for example, (a) amino acids having uncharged polar side chains, such as asparagine, glutamine, serine, threonine, and tyrosine; (b) amino acids having basic side chains, such as lysine, arginine, and histidine; (c) amino acids having acidic side chains, such as aspartic acid and glutamic acid; and (d) amino acids having nonpolar side chains, such as glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, and cysteine.

Id at pg. 9, lines 8–14. Thus, Applicants assert that one of ordinary skill in the art could make and use such homologous sequences in, for example, vaccines and diagnostic reagents. Accordingly, Applicants respectfully request reconsideration and withdrawal of the present rejection.

35 U.S.C. §112, Second Paragraph Rejections

The Examiner has rejected claims 3, 4, 13, 17 and 19 under 35 U.S.C. §112, second paragraph, as being indefinite for improper antecedent basis.

Applicants have amended claims 3 and 4 to correct antecedent basis. Thus, claims 3 and 4 now recite "polynucleotides." Basis for these amendments can be found in the specification as originally filed, and in particular, in originally filed claims 1 and 2. Applicants have amended claim 13 to correct improper dependency. Thus, claim 13 now recites "the host cell of claim 12." Applicants have amended claim 19 to correct improper dependency. Thus, claim 19 now recites "the vaccine vector of claim 16." Applicants have added new claims 38 and 39 to more accurately claim the present invention. New claims 38 and 39 further limit the type of host cells to be used in the present invention. Specifically, new claims 38 and 39 are directed to mammalian cells and human cells respectively. Basis for these amendments can be found in the specification as originally filed, and in particular, at pg. 14, lines 9–14; pg. 15, line 31; and in originally filed claim 17.

In light of the above amendments, Applicants believe that the present rejections are now moot. Accordingly, Applicants respectfully request reconsideration and withdrawal of the present rejections.

35 U.S.C. §102 Rejection

The Examiner has rejected claims 1–4, 10–13, 16–19, 25 and 26 under 35 U.S.C. §102(b) as being anticipated by Longbottom *et al.* (**Longbottom**). Specifically, the Examiner has stated that **Longbottom** teaches “*chlamydial* genes or sequences coding for highly immunogenic protein fragments comprising 8 or 9 amino acid residues.”

Applicants traverse. **Anticipation requires the disclosure in a single prior art reference of each element of the claim under consideration.** *W.L. Gore & Associates v. Garlock, Inc.*, 220 USPQ 303, 313 (Fed. Cir. 1983), *cert. denied*, 469 U.S. 851 (1984); *Connell v. Sears Roebuck & Co.*, 220 USPQ 193, 198 (Fed. Cir. 1983); *Verdegaal Bros. v. Union Oil Co. of California*, 2 USPQ2d 1051, 1053 (Fed. Cir. 1987); *In re Spada*, 15 USPQ2d 1655 (Fed. Cir. 1990); MPEP § 2131. **“There must be no difference between the claimed invention and the reference disclosure, as viewed by a person of ordinary skill in the field of the invention.”** *Scripps Clinic & Research Foundation v. Genentech Inc.*, 18 USPQ 2d 1001, 1010 (Fed. Cir. 1991).

Although both applications are directed to *Chlamydia* polypeptides, **Longbottom** discloses distinct sequences encoding *different Chlamydia* polypeptides. Applicants have attached herewith an alignment comparison between the polypeptides of the present application with those disclosed by **Longbottom** (Exhibit C1 to C4). Applicants have highlighted the regions that the Examiner has suggested would be identical between the present application and **Longbottom**. As can be seen by the highlighted regions, the rejection seems to be based upon that of identical fragments within the polynucleotides and/or polypeptides of the present invention, **not on the entire polynucleotide or polypeptide**. Furthermore, the comparisons clearly show that the polynucleotides and polypeptides according to the present invention are, in

Applicants: Murdin *et al.*
Serial No. 09/428,122

fact, **different** from those disclosed in **Longbottom**. Thus, Applicants assert that the present application is not anticipated by **Longbottom**.

Accordingly, in light of the arguments above, Applicants respectfully request reconsideration and withdrawal of the present rejection.

CONCLUSION

On the basis of the foregoing amendments and remarks, Applicants respectfully submit that the pending claims are in condition for allowance. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Michel Morency, Reg. No. P-50,183
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: December 4, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

The paragraph beginning at line 6, pg. 8 was amended as follows:

-- [FIG. 1] FIG. 1A to 1I shows the nucleotide sequence (top sequence) and the deduced amino acid sequence (bottom sequence) of the full length *98 kDa putative outer membrane protein* gene (SEQ ID NO: 1) and the processed sequence from *Chlamydia pneumoniae* (SEQ ID NO: 2). --

The paragraph beginning at line 9, pg. 8 was amended as follows:

-- [FIG. 2] FIG. 2A to 2H shows the restriction enzyme analysis of nucleotide sequence encoding the *C. pneumoniae* *98 kDa putative outer membrane protein* gene. --

The paragraph beginning at line 13, pg. 16 was amended as follows:

A recombinant expression system can be selected from prokaryotic and eukaryotic hosts. Eukaryotic hosts include yeast cells (*e.g.*, *Saccharomyces cerevisiae* or *Pichia pastoris*), mammalian cells (*e.g.*, COS1, NIH3T3, or JEG3 cells), arthropods cells (*e.g.*, *Spodoptera frugiperda* (SF9) cells), and plant cells. Preferably, a prokaryotic host such as *E. coli* is used. Bacterial and eukaryotic cells are available from a number of different sources to those skilled in the art, *e.g.*, the American Type Culture Collection [(ATCC; Rockville, Maryland)] (ATCC; 10801 University Boulevard, Manassas, VA 20110-2209).

In the Claims:

3. (Amended) The polynucleotide of claim 2 wherein the fusion polypeptide is a heterologous signal peptide.

4. (Amended) The polynucleotide of claim 2 wherein the polynucleotide encodes a functional fragment of the polypeptide having the SEQ ID NO: 2.
13. (Amended) The host cell of claim 12[0], wherein said host cell is a prokaryotic cell.
19. (Amended) A pharmaceutical composition, comprising an immunologically effective amount of the vaccine vector of claim 16[4].
25. (Amended) A polynucleotide probe reagent capable of detecting the presence of *Chlamydia* in a biological material, comprising a polynucleotide that hybridizes to the polynucleotide of claim 1 under stringent conditions.
- 38. (New) The host cell of claim 14, wherein said eukaryotic cell is a mammalian cell.
39. (New) The host cell of claim 38, wherein said mammalian cell is a human cell.--

TRA 1460374v2

EXHIBIT C - The Alignment of LONGBOTTOM to CPN 100396 (SEQ ID NO:1)

Alignment 1

GAP of: cpu72499.seq check: 4475 from: 1 to: 4926

WPDEF Chlamydophila abortus putative outer membrane protein gene, partial
LOCUS CPU72499 4926 bp DNA BCT 13-MAY-1999
DEFINITION Chlamydophila abortus putative outer membrane protein gene, partial
cds; and putative 98 kDa outer membrane protein gene, complete cds.
ACCESSION U72499
VERSION U72499.1 GI:1657776 . . .

to: cpn100396.seq check: 452 from: 1 to: 3000

WPDEF
cpn100396

Symbol comparison table: /big1/gcg/gcgccore/data/rundata/nwsgapdna.cmp
CompCheck: 8760

Gap Weight: 50 Average Match: 10.000
Length Weight: 3 Average Mismatch: 0.000

Quality: 14521 Length: 5027
Ratio: 4.840 Gaps: 13
Percent Similarity: 53.087 Percent Identity: 53.087

Match display thresholds for the alignment(s):
| = IDENTITY
: = 5
. = 1

cpu72499.seq x cpn100396.seq March 2, 2001 11:29 ..

1951 CAAGCAGTCCTCTCTAGAACGCAGGGGCCTTTACCAAAATGACAAAAA 2000

1 cgctct 6

2001 CATGTCAAGTCTTCTGTATTAGACTTGCTTCTTGTATCTTGAGT 2050

7 taccttagtagaggtgagtgaatttcttgacttgtttcttatgggtgt 56

2051 ATTTAACGAAACTGTTTTTCATTCACCACA.AGTGTATAAAATGAGG 2099

57 atctctaaaatattaaattcaaaatcaaagtatatatttacaatgaag 106

2100 CCTTCTTATATAAGATTTAATATCGTCGACGCTGACGTTACCAATATC 2149

107 tcttccttcccaagttgtatattctacatgtctatcccttgc 156

2150 TTTTCACTCTCGCAATTGCATGCAGAAGTGGCTTAACCAAGAAC 2199
| | | | | | | | | | | | | | | | | | | | | | | | | |
157 tatgattgctac.....cgagacagtttggattcaagtgcgagttcg 200

2200 TTCTCGATGCAAATGGAGCATTCACTCCGAACTACAAGCACTGCGGG 2249
| | | | | | | | | | | | | | | | | | | | | | | | | |
201 atggaaataaaaaatgtaattttcagttcgtgagagttagaaatgct 250

2250 GGAACGATTACAACGTCGAGAGTGTATTTCTATTGTAGATGTAGGACA 2299
| | | | | | | | | | | | | | | | | | | | | | | | | |
251 ggaactacctacctatTTAaggaaatgtcactctagaaaatattcctgg 300

2300 GACAG...CGGCTCTGCTTCCTCAGCTTTGTTCAACTGCAGACAACC 2346
| | | | | | | | | | | | | | | | | | | | | | | | | |
301 aacaggcacagcaatcacaaaaagctgtttacaacactaaggcgatt 350

2347 TAACTTCAAAGGAACAACCATAGCTTATCCATAACGAACCGAATGCC 2396
| | | | | | | | | | | | | | | | | | | | | | | | | |
351 tgactttcacaggtaacggaaactctctattgttccaaacgggtggatgca 400

2397 GGAGCTAATCC...TGCGGGAAATTAACGTTAACACTGCCGATAAGATTCT 2443
| | | | | | | | | | | | | | | | | | | | | | | | | |
401 gggactgttagcagggctgttacacagcagcgtggtagataatctac 450

2444 TACGCTGACAGATTTCTAAGTTGAGCTTAAAGGAATGCCCATCTTCTC 2493
| | | | | | | | | | | | | | | | | | | | | | | | | |
451 cacgttatagggtttctcgatatTTTattgcgtctcctggaagtt 500

2494 TAGTGAATACTGGAAAAGGGC...TATGAAATCCGGAGGAGCATTAAAC 2540
| | | | | | | | | | | | | | | | | | | | | | | | | |
501 cgataactaccggcaaaggagccgttagctgctacggtagcttgagt 550

2541 TTAGCGAATAATGCCAGTATTCTGTTGATCAGAACTATTCCGCTGAGAA 2590
| | | | | | | | | | | | | | | | | | | | | | | | | |
551 ttgacaaaaaatgtcagttgcTTcgttacggaaactttcaacggataa 600

2591 TGGTGGAGGCATCTCTGCAAAGCTTTCTCTAACCGGCTCGAGCAAAG 2640
| | | | | | | | | | | | | | | | | | | | | | | | | |
601 tggcggtgttatcaccgcggaaaactctttatTTacaggactacaatgt 650

2641 AAATCAGCTTCACCACTAACTCTACTGCGAAAAAAGGTGGAGCGATTGCT 2690
| | | | | | | | | | | | | | | | | | | | | | | | | |
651 cagctctttctggaaaataccctctaaaggaaaggcgccattcag 700

2691 GCTACGGGAATAGCTCATCTTCGGACAACCAAGGCACAATCAGATTTC 2740
| | | | | | | | | | | | | | | | | | | | | | | | | |
701 acttccgatgcccttaccattactggaaaccaaggaaagtcttttttc 750

2741 TGGGAACACTGCTGTGAATTCTGGGGAGCAGTATATTCAAGCTTCTA 2790
| | | | | | | | | | | | | | | | | | | | | | | | | |
751 tgacaataacttcttcggattctggagctgcaattttacagaaggctcg 800

2791 TGACGATTGCAGGTAAACAACCAACCGTTGCTTTAGCAACAAATGCTGTTCC 2840
| | | | | | | | | | | | | | | | | | | | | | | | | |
801 tgactattctaataatgctaaagttcTTTattgacaataaggcaca 850

2841 GG.....TTCATCTGATGGTTGCGGTGGAGCTATCCATTG 2875

1545 aacctgctgatactagcaccataaacaattggtcattaacatcagtct 1594
3561 TTAGATGGGAAAAAAATTGCCGTAGTCGATGCCGTTGCTGCTGGGAAGAA 3610
1595 atagacggtgcaaagaaggcaaaaatagaaaccaaagctacgtcaaaaaa 1644
3611 TGTGACTTTATCAGGTGCTATTGGCGTTATTGATCCTACAGGGAAAGTTT 3660
1645 tctgactttatctggaaccatcactttatggacccgacgggcacgtttt 1694
3661 ATGAAAACCATAAGCTAAATGATACGTTAGCTTAGGAGGAATTCAACCT 3710
1695 atgaaaatcatagttaaagaaatcctcagtcctacgacatcttagagctc 1744
3711 TCTGGGAAAGGTTCGGTGACAACAAACCAACGTGCCTAGTCATGTTGGTGG 3760
1745 aaagcttctggaactgtaacaaggcaccgcagtgactccagatcctataat 1794
3761 TGTTGCTGAAACCCACTATGGTTATCAAGGAAACTGGTCTGTCAGTTGGG 3810
1795 gggtagagaaattccattacggctatcaggga.....acttggg 1832
3811 TCAAAGATAATAACTCTGATCCTAAAAACACAAACAGCAATTTACCTGG 3860
1833 gcccaattgttggggacaggggctctacgactgcaaccttcaactgg 1882
3861 AATAAACAGGATATGTTCCAATCCTGAACGTCGTGCTCCGCTAGTACT 3910
1883 actaaaactggctatattcctaattcccagcgatcgcttttagtccc 1932
3911 CAATAGCCTTGGGATCCTTATAGATTACGTTCTATTCAAGATGTCT 3960
1933 taatagcttatggaatgcatttatagatattagctctccattatctta 1982
3961 TGGAACGTAGTGTTGATAGTATTCTTGAGACACGTCGTGGTTGTGGTC 4010
1983 tggagactgcaaacgaagggttgc...agggagaccgtcttttgtgt 2029
4011 TCTGGAATTGGGAACTTCTCCATAAAGATCGGAATGCTGAAAATCGCAA 4060
2030 gctggattatctaacttcttcataaggatagtacaacaaacacgacgcgg 2079
4061 ATTCCGTCATATCAGTCGGGATATGTGTTAGGAGGCCACAACAAATACCT 4110
2080 gtttcgcatttgagttggcggttatgtcataggagaaacctacatactt 2129
4111 CGAGAGAGGATTCTCTTAGTGTGGCTTCTGTCAGTTATTGCAAAAGAT 4160
2130 gttcagataagattcttagtgctgcatttgcagctcttggaaagagat 2179
4161 AAAGACTACCTTGTAAGCAAGAACGCCGAAACGTCTATGCGGGTTCTGT 4210
2180 agagactactttgttagctaagaatcaaggtagtctacggaggaactct 2229
4211 ATATTATCAGCATGTGAGCAAGTTGATGATCTCACCGCGTTATTTAATG 4260
2230 ctattaccqca.....caacqaaacctatctcttccttgcqcaac 2273

4261 GGCCTAACACGTGTTCAAGGGTTCTAAAGAGATTCCATTTCCTTG 4310
 | | | | || | || | || | || | || | || | || |
 2274 tacggccttgttcgttgcttatgttccatcacagagattcctgttcttt 2323

 4311 GATGCACAAATTACCTATTGCCACACGGCCAACAACATGACAACGTCCTA 4360
 | | | | || | || | || | || | || | || | || | || |
 2324 tcaggaaaccttagctacacccatacggataacgatctgaaaaccaagta 2373

 4361 TACAGACTATCCTGAAGTGAAAGGTTCTGGGTAATGATAACCTGGGCT 4410
 | | | | || | || | || | || | || | || | || | || |
 2374 tacaacatatcctactgttaaggaagctggggaatgatagttcgctt 2423

 4411 TAACTTGTCTACTAGCGTACCTATCCCGTATTAGTTCTTCTATCTTT 4460
 | | | | | | | || | || | || | || | || | || | || |
 2424 tagaattcggtgaaagagctccgatttgcttagatgaaagtgcgtctattt 2473

 4461 GATAGTTATGCACCGTTGCAAAATTACAAGTTGTCTATGCGCACCAAGA 4510
 | | | | | | | || | || | || | || | || | || | || |
 2474 gagcagttacatgcccttcatgaaattgcagttgtctatgcacatcagga 2523

 4511 TGACTTTAAAGAACCAACAAACAGAAGGCCGGTCTTGAAAGCAGCGATC 4560
 | | | | | | | || | || | || | || | || | || | || |
 2524 aggtttaaagaacacagggAACAGAGCTCGTGAATTGGAAGTAGCCGTC 2573

 4561 TTCTCAACGTTCTGTACCTATAGGTATAAAATTGAGAAACTCTCCTAT 4610
 | | | | | | | || | || | || | || | || | || | || |
 2574 ttgtgaatcttgcccttacctatcggatccgatttgataaggaatcagac 2623

 4611 GGAGAGAGAAGTGCCTATGATCTTACACTGATGTATACCTGATGTGTA 4660
 | | | | | | | || | || | || | || | || | || | || |
 2624 tgccaagatgcaacgtacaatctaactcttggttatactgtggatcttgt 2673

 4661 CCGTCATAATCCAAGCTGTATGACAGGATTGGCGATCAATGACGTTCCCT 4710
 | | | | | | | || | || | || | || | || | || | || |
 2674 tcgttagtaaccccgactgtacgacaaacactgcgaattagcggtgattctt 2723

 4711 GGTAAACCACAGCTACGAATCTGCTAGACAAGCTTCATAGTCGCGCG 4760
 | | | | | | | || | || | || | || | || | || | || |
 2724 gaaaaacccctcggtacgaatttggcaagacaagctttagtcctcgtca 2773

 4761 GGTAACCATATTGCCTAACCTCTGGTGTGAGATGTTCAAGTCAGTTGG 4810
 | | | | | | | || | || | || | || | || | || | || |
 2774 gggaccattttgccttaactcaaatttgaagcctttagccaattttc 2823

 4811 TTTCGAATTACGAAGCTCTCAAGAAATTATAACGTAGATCTGGCGCTA 4860
 | | | | | | | || | || | || | || | || | || | || |
 2824 ttttgaattgcgtgggtcatctcgcaattacaatgttagacttaggagcaa 2873

 4861 AGGTCGCGTTCTAAAAAGCTCCCCCTGCCAGCTGGCAGGGTTCTC 4910
 | | | | | | | || | || | || | || | || | || | || |
 2874 aataccaattctaattgcgttagcttggtaaagagctccatacatcgaag 2923

 4911 CTTATTCTAGTCTAGA..... 4926
 | | | | |
 2924 gaaaaagagctttaagatttcttgaaggctttcgatttcgatttcc 2973

Alignment 2

GAP of: cpu65942.seq check: 1642 from: 1 to: 6110

WPDEF Chlamydophila abortus strain S26/3 POMP91A and POMP90A precursor,
LOCUS CPU65942 6110 bp DNA BCT 07-MAY-1999
DEFINITION Chlamydophila abortus strain S26/3 POMP91A and POMP90A precursor,
genes, complete cds.
ACCESSION U65942
VERSION U65942.1 GI:1617505 . . .

to: cpn100396.seq check: 452 from: 1 to: 3000

WPDEF
cpn100396

Symbol comparison table: /big1/gcg/gcgcore/data/rundata/nwsgapdna.cmp
CompCheck: 8760

Gap Weight: 50 Average Match: 10.000
Length Weight: 3 Average Mismatch: 0.000

Quality: 13146 Length: 6140
Ratio: 4.382 Gaps: 20
Percent Similarity: 49.428 Percent Identity: 49.428

Match display thresholds for the alignment(s):

| = IDENTITY
: = 5
. = 1

cpu65942.seq x cpn100396.seq March 2, 2001 13:39 ..

2251 CTTTAAGGAAAACAATAGCGATCAAGGAAGATACTTGAAAGTAATAACC 2300
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
1cgctcttacctaqtatqaggttqagtqaatttctt 34

2301 TCACCAACTTATCTATGCCCATAGGTGTGAAATTGGAAAAATTCTCTCAC 2350
| | ||| | | | | | | | | | | | | | | | | | | | | | | | | | | |
35 gacttgtttctccattggtgtatctcttaaaatattaaaattcaaaaatca 84

2351 AAGGATACCGCTTCTTACAACCTTACCCCTGGCTTATGCTCCAGATATCGT 2400
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
85 aagtatataattttacaatgaagtcttctttcccaagttgtatTTCTA 134

2401 AAGAAGCAACCCTGACTGTACTGCCCTCTGTAGTGAGCCCAACCTCTG 2450
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
135 catttgc.....tatttcccttgtctatgattgtaccgaga 173

2451 CTGTCTGGGTAACCTAAAGCTAATAACCTTGCAGCGGGATGCTTCATATT 2500
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
174 cagttttggattcaagtgcgagttcgatggaaataaaaaatggtaatttt 223

845 gtcacaggagcgagctcctcaacaacggggatatgtcaggagggtctat 894
 3251 TATCCAGTGTAAAGGAAGCAGTGATGCTGAATTAAAAATAGAAAATAATC 3300
 895 ctgtgcttataaaacttagtacagatactaaggtcacccctcactggaaatc 944
 3301 AGAATCTGGTTTCAGAAAACCTCCACTTCAGGCGGGCTATT 3350
 945 agatgttactcttcagcaacaatacatcgacaacagcggaggagctatc 994
 3351 TATGCTGATAAAACTCACCATGTCTCAGGTGGGCCTACATTATTTCTAA 3400
 995 tatgtgaaaagctcgaaactggctccggaggacttaccctattcagtag 1044
 3401 CAACTCTGTATCCAACGGTTCATCCCCTAAAGGCGGAGCTATTAGCATAA 3450
 1045 aaatagtgtcaatggaggtacagctcctaaaggtggagccatagctatcg 1094
 3451 AAGATTCAAGTGGTGAATGTAGCCTAACCGCTGATCTGGAGATATTACC 3500
 1095 aagat...agtgggaatttagtttatccggatagtggacattgtc 1141
 3501 TTGATGGGAACAAAATCATCAAACAGGGAAATTACAAAGCTACGTGCTA 3550
 1142 ttttaggaatacagtcaacttctactactcctgg.....gacgaatag 1185
 3551 AAGAAATTCCATAGATCTGGCACAGGGAAATTACAAAGCTACGTGCTA 3600
 1186 aagtagtatcgacttaggaacgcgatgtcaaagatgacagcttgcgttctg 1235
 3601 AAGACGGCTTCGGAATTTCCTCTATGACCTATTACTGGGGAGGAT.. 3648
 1236 ctgctggtagagccatctacttctatgatcccataactacaggatcatcc 1285
 3649CTGATGAACTAACATTAATAA.....AAAAGAAC 3679
 1286 acaacagttacagatgtctaaaagttaatgagactccggcagattctgc 1335
 3680 TGTTGATTATACAGGAAAGATCGTCTCTCAGGTGAAAAATTATCCGATG 3729
 1336 actacaatatacagggAACATCATCTCACAGGAGAAAAGTTATCAGAGA 1385
 3730 AAGAAAAAGCACGAGCGGAAACCTAGCTTCTACTTCACCAACCCATC 3779
 1386 cagaggcccgacattctaaaaatcttacttcgaagctactacacgcctgta 1435
 3780 ACATTATCAGCAGGATCTCTGTACTTAAAGATGGTGTATCTGTAACCGC 3829
 1436 actctttcaggaggtaactctatcttaaaacatggagtgactctgcagac 1485
 3830 AAAACAAGTAACGCAGGAAGCGGGATCTACCGTTGTATGGATCTAGGGA 3879
 1486 tcaggcattcaactcaacaggcagattctcgatcgaaatggacgttaggaa 1535
 3880 CCACATTACAGACGCCTCTTCAGGTGGAGAAACCATCACCTAACTAAT 3929

1536 ctactctaga.....acctgctgatactagcaccataaacaat 1573
3930 CTAGATATTAAACATCGCCTCGTTGGGGGGGGGGGTACCTCTCCTGC 3979
1574 ttggtcattaaacatcagttctat.....agacggtgcaaagaaggc 1614
3980 TAAACTCGAACAAATACAGCAAGTCAAGCTATAACTAT...TAACGCTG 4026
1615 aaaaatagaaaccaagctacgtcaaaaaatctgactttatctggaacca 1664
4027 TCAATCTAGTCGATGCTGATGGCAATGCTTATGAAGATCCTATTCT... 4072
1665 tcactttattggaccgcacggcacgttttatgaaaatcatagtttaaga 1714
4073 ..TGCTACGTCTAAACCTTTCACAGCAATAGTAGCTACAACTAACGCTAG 4120
1715 aatcctcagtcctacgacatcttagagctcaaagctctggaactgtaac 1764
4121 TACAGTCACACAGCCTACAGATAATCTAACAAATTATGTCCCTCCTACTC 4170
1765 aagcaccgcagtgactccagatcctataatgggtga.....gaaattcc 1808
4171 ATTACGGTTACCAAGGAAATTGGACAGTAACTTGGGACACCGAACAGCT 4220
1809 attacggctatcagggacttggggcccaattgtttggggacaggggct 1858
4221 ACAAAAACAGCCACTCTAACCTGGAACAAACTGGCTACTCCCCTAACCC 4270
1859 tctacgactgcaaccttcaactggactaaaactggctatattcctaattcc 1908
4271 AGAACGTCAAGGACCTTAGTCCCAGAATACTCTTGGGTGCATTCTCTG 4320
1909 cgagcgtatcggtcttttagtcctaatagcttatggaatgcattttag 1958
4321 ACCTCAGAGCTATACAAAACCTTAATGGATATTAGCGTCAATGGCGCTGAC 4370
1959 atattagctctccattatcttatggagactgcaaacgaagggttgcag 2008
4371 TACCATAGAGGTTTGGTATCCGGCTAGCTAACCTTACACAAAAG 4420
2009 ggagaccgtgctttgggtgtggattatctaaattttccataagga 2058
4421 TGGCTCTGATACTAAACGCAAGTTCCGTACAATAGCGCCGGATACGCTT 4470
2059 tagtacaaaaacacgacgcgggttgcgcattttagtggcggttatgtca 2108
4471 TAGGCGTCTACGCAAAAACCTCTGATGATATTTCAGTGGGCTTTC 4520
2109 taggaggaaacctacatacttggtagataagatttttagtgcattt 2158
4521 TGCCAACTCTCGGAAAGGACAAAGACTATTTAGTGTGAAAAACACGC 4570
2159 tgcgtacgtttggaaagagatagagactactttagtgcatttgcattt 2208
4571 CAACATTTACGCAGGTTCTCTATTATCAGCATATCTCCTATTGGAGCG 4620
2209 tacacgtctacqqaqqaactctctattaccacqacaacqaaaccttatatct 2258

4621 CTTGGCAGAACATCTGCTACAAAACACTATCGGTGCAGAAGCTCCGTAGTC 4670
|| | || | || | | | | | | | | | | | | | | | |
2259 ctcttccttgc当地actacggccttgc当地gtcttatgttcc当地acagag 2308

4671 CTTAACGCACAGTTAACCTATTGTCATGCTCAAACGACATGAAAACCAA 4720
| | | | | | | | | | | | | | | | | | | | | |
2309 attcctgttctttcaggaaaccttagctacacccatacgataacga 2358

4721 CATGACGACTACTTACGCTCCTCGTAAAACAACGTATGCAGAAATCAAGG 4770
| | | | | | | | | | | | | | | | | | | | | |
2359 tctgaaaaccaagt.....atacaacatatacctactgtttaag 2396

4771 GTGATTGGGGTAACGATTGTTCGGAGTCGAGCTTGGTGCAACTGTGCCT 4820
| | | | | | | | | | | | | | | | | | | | | |
2397 gaagctggggaaatgatagtttc当地ctt当地agaattc当地ggtaagagctccg 2446

4821 ATCCAAACAGAACATCTCTCCTATTGATATGTAACACCTTCTGAA 4870
| | | | | | | | | | | | | | | | | | | | | |
2447 atttgcttagatgaaagtgc当地tattt当地gagc当地gatgc当地ccctt当地atgaa 2496

4871 GTTTCAACTTGTGCATACGCACCAAGATGACTTAAGGAAAACAATAGCG 4920
| | | | | | | | | | | | | | | | | | | | | |
2497 attgc当地gtt当地tcatgc当地cacatc当地agga当地agg当地tttaa当地agaacagg当地aaacag 2546

4921 ATCAGGGAAAGATACTTCGAAAGCAGCAATCTCACCAACCTTCTGCCT 4970
| | | | | | | | | | | | | | | | | | | | | |
2547 ...aagctc当地gtgatattt当地gagtagcc当地gtt当地gtgatattt当地gc当地ctt当地tacact 2593

4971 ATCGGCATCAAGTTGAGAGATTGCTAACAAACGATAACAGCTTCTTATCA 5020
| | | | | | | | | | | | | | | | | | | | | |
2594 atc当地ggg当地atcc当地gatattt当地gataagga当地atc当地agactgc当地caagatgc当地aacgtacaa 2643

5021 TGTCACTGCTGCTTATTCTCCTGATATCGTAAGAAGTAACCCCTGACTGTA 5070
| | | | | | | | | | | | | | | | | | | | | |
2644 tctaactctt当地ggg当地tatactgt当地ggatctt当地gtc当地tagtaacc当地ccgactgtta 2693

5071 CTACTTCTCTGTTAGTAAGCCCCGACTCTGCTGTCTGGTAACGAAAGCC 5120
| | | | | | | | | | | | | | | | | | | | | |
2694 cgacaacactgc当地gaattt当地tagc当地gggt当地gattct.....tggaaaacctt当地cggt 2737

5121 AACAAACCTTGCAGAACGCGCTTCATGCTACAAGCAGGAAACTACTTGTC 5170
| | | | | | | | | | | | | | | | | | | | | |
2738 acgaatattt当地ggcaagacaagactt当地tagtc当地tcc当地gtc当地cagg当地aaaccattttg 2787

5171 TTAAAGTCACAACATAGAAATCTCAGCCAGTTCGGTTTCGAGCTCAGGG 5220
| | | | | | | | | | | | | | | | | | | | | |
2788 cttaactcaaattt当地gaagc当地ctt当地tagcc当地attt当地ctt当地gaattt当地gc当地gt 2837

5221 GATCTTCACGAACCTATAACGTAGATCTCGGATCGAAGATCCAGTCTAA 5270
| | | | | | | | | | | | | | | | | | | | | |
2838 ggtcatctc当地gcaattacaatgttagacttaggagcaaaatccaattctaa 2887

5271 TCTCATCCACCTCTCCTACCCCCGTTCCCACGGGGTAGGGCCTTATAACCT 5320
| | | | | | | | | | | | | | | | | | | | | |
2888 t.gcgtagctt当地ggtaaagagactcc当地atcatc当地gaaagg当地aaaqagctt 2936

5321 TGACTCTCCTTGGAAATATCCCGAACAAAGAGTCAAAAAAAATACGTCTCAT 5370
| | | | |||| | | | | | | | | | | | | | | | | | | | | | | | | |
2937 taagatttcttqaaggcttttcgatttcgattccattttagtgtttt 2986

5371 AGGATTCTGGTCTATTCCTTTCTTATTTGGAGAAAAATCTGATCAC 5420
| | |
2987 qctaaaacactttc..... 3000

Alignment 3

GAP of: pomp90.pep check: 1153 from: 1 to: 839

WPDEF prt
pomp90 prt

to: 396prt.pep check: 2118 from: 1 to: 928

WPDEF
396prt

Symbol comparison table: /big1/gcg/gcgcore/data/rundata/blosum62.cmp
CompCheck: 6430

BLOSUM62 amino acid substitution matrix.

Reference: Henikoff, S. and Henikoff, J. G. (1992). Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. USA 89: 10915-10919.

Gap Weight: -8 Average Match: 2.912
Length Weight: 2 Average Mismatch: -2.003

Quality: 1485 Length: 958
Ratio: 1.770 Gaps: 29
Percent Similarity: 54.512 Percent Identity: 47.960

Match display thresholds for the alignment(s) :

| = IDENTITY
: = 2
. = 1

pomp90.pep x 396prt.pep March 2, 2001 16:59 ..

1 MKHPVYWFLLSSSLFASNSLSFANDAQTALTPSDSYNGNVTSEEFQVKET 50
|| . | . || :| | | :|| . | | :|. 1 mkssfpkfvfst..faifpolsmi.attetylldssasfdgn.kngnfsyres 46

51 ..SSGTTYTCEGNVCI.SFAGKDGLKKSCFSAT.DNLTFLGNGYTLCFD 96
.....|||| .||| : . | . : ||||. | .||| ||| .| |
47 gedatgattyfkgnutloningstataitkccsfptkldltftanpanllfg 96

144 GNTTLKD NSSL VFHKNCST AEG 165
| . . | | || . | | | | |

166 GAIQ..... 169

197 gaiqtsdaltitgnqgevsfsdntssdsgaaifteasvtisnnakvsfid 246

170 C. KGSSDAEJKIENNOLVESENSSTS KGG 198

| | | . | .. : | | | . | | | . | | |

199 AIYADKLTIVSGGPTLFSNNSVNSNGSSPKGGAIISIKDSSGECSLTADLGD 248
|| | : ||| |||. . . |||||. . | ||| ||.|| |
297 aiyvkklelasggltlfsrnsvnggtapkggiaied.sgelslsadsgd 345

249 ITFDGNKIIKTSIGGSSTVTRNSIDLGT.GKFTKLRAKGFGIFFYDPITG 297
| | | : |.||||| | | |||. | | : |||||
346 ivflgntvtsttppgtn..rssidlgtsakmtalrsaagraiyfydpitt 392

298 GGS....DELNINK...KETVDYTGKIVFSGEKLSDEEKARAENLASTFN 340
| | | | | : . . . | | | | : . | | . ||| | | | | |
393 gssttvtdvlkvnetpadsalqytgniftgeklsseteaadsknltksll 442

341 QPITLSAGSLVLKDGVSVTAKQVTQEAGSTVVMDLGTTLQTPSSGGGETIT 390
|| : || | . | | | | . . | | : | . || . || | : | . : | |
443 qptlsggtlslkhgvtlqtqaftqqadsrlemdvgttle.pa...dtst 488

391 LTNLDINIASLGGGGTSPAKLATNTASQAITIN.AVNLDADGNAYEDP 439
: | | | . : | | | | : | . : | .. : | . | | | | |
489 innlvinissi...dgakkakietkatsknltisgtitlldptgtfyenh 535

440 ILATSKPFTAI...VATTNASTVTQPTDNLTNYVPPTHYGYQGNW.TVTW 485
| . : : . | | | | | : | | | | | : | | | | | : |
536 slrnnpqsydilelkasgtvtstavtp.dpimg..ekfhygyqgtwgpiwv 582

486 DTETATKTATLTWEQTGYSPNPERQGPLVPNTLWGAFSDLRAIQNLMDIS 535
| . | | | | . | | | | | | | | | | | | | | | | : .. | | : .
583 gtgast.tatfnwtktgyipnperigslvpnslnafidisslhylmeta 631

536 VNGADYHRGFVWVGLANFLHKSGSDTKRKFRHNSAGYALGVYAKTPSDDI 585
| | | | . || | | | . | : | | | | | | | | | | | | |
632 neglqgdrafwcaglsnffhkdstktrrgfrhlsrgyvigglnhtcsdk 681

586 FSAAFCQLFGKDYLVSKNNAIYAGSLYYQH...ISYWSAWQNLLQN 631
| | | | | : | : | | | . | : | | | | | | | | | | | | | |
682 lsaafcqlfgdrdyfvaknqgtvyyggtlyyqhnetyislpcklrpcsls 731

632 TIGAEAPLVNQLTYCHASNNDMKTNMNTTYAPRKTTYAEIKGDWNDCF 681
: | | .. | . | | | | : | | | | | | | | | | | | | | | |
732 yvpteipvlfsgnlsyhtndlkt.....kyttyptvkgswnsd 773

682 GVELGATVPIQTESSLFLDMYSPFLKFQLVHTHQDDFKENNNSDQGRYFES 731
. | | | | : | | | : | | | | | | | | | | | | | | | | | |
774 alefggrapicldesalfeqympfmklqfvyahqegfkeqgt.earefgs 822

732 SNLTNLSLPIGIKFERFANNDTASYHVTAAYSVDIVRSNPDCITSLVSP 781
| | | | . | | | | : | : .. | . | . | : | | | | | | | | | |
823 srlvnlaalpigirfdkesdcqdatynltlgytvdlvrsnpdcttlrisg 872

782 DSAVWVTKANNLARSAFMLQAGNYLSLSHNIEIFSQFGFELRGSSRTYNV 831
| | | | | | | | | . | | | : . | | | | | | | | | | | | | | |
873 ds..wktfgtnlarqalvragnhfcfnnsfeafsqfsfelrgssrnynv 920

832 DLGSKIQF 839
| | . | | |
921 dlqakyqf 928

Alignment 4

GAP of: pomp91.pep check: 2232 from: 1 to: 847

WPDEF prt
pomp91 prt

to: 396prt.pep check: 2118 from: 1 to: 928

WPDEF
396prt

Symbol comparison table: /big1/gcg/gcgcore/data/rundata/blosum62.cmp
CompCheck: 6430

BLOSUM62 amino acid substitution matrix.

Reference: Henikoff, S. and Henikoff, J. G. (1992). Amino acid
substitution matrices from protein blocks. Proc. Natl. Acad.
Sci. USA 89: 10915-10919.

Gap Weight: 8 Average Match: 2.912
Length Weight: 2 Average Mismatch: -2.003

Quality: 1468 Length: 967
Ratio: 1.733 Gaps: 29
Percent Similarity: 51.238 Percent Identity: 44.059

Match display thresholds for the alignment(s):

| = IDENTITY
: = 2
. = 1

pomp91.pep x 396prt.pep March 2, 2001 17:01 ...

1MKHPVYWFLISS 12
51 gttylfkgnvtlenipgtgtaitkscfnntkgdltftgngnsllfqtvda 100
13 SLIVSNSLYSEEPDQKTLTSAHSYNGNTNSEP FNPLSTSNSNGTIYTCTG 62
101 gtvagaavnssvvdksttfigfs.slsfiaspgssitt..gkgavscstg 147
63 NICIAYAGLDGSGLSSSCF.TD.....TAGNLSFLGNGYTLCFDNITTQS 106
148 slslt...knvslifsknfstdnggaitaktlsltgttmsalfse.ntss 193
107 SHPGAISVSGTNKTL DISGFSLFSCAYC PPGATGYG.AIKAVGNTTIKDN 155
194 kkggaiq...tsdaltitg.nqgevsfsdntssdsgaai fteasvtisnn 239
156 SSLVFHKNCSTG.....EGGAIQCKASSSEAE LKIENNQNLVFAEN 196
240 akvsfidnkvtgasssttgdmsggaicayktstdkvltgnqmqllfsnn 289

